The page pro.biontech.com is not accessible from your location. You have been redirected to our corporate website for more information and resources.
Breakthrough technologies to revolutionize medicine
25
+
Phase 2 and phase 3 clinical trials in oncology
10
Novel-novel combination trials
2.1
bn €
Investment into R&D in 2025 to address cancer care across indications with high incidence
Sign up for our email alert for news on our growing pipeline
